FDA, CMS To Standardize Regulatory Analytical Tools
This article was originally published in The Gray Sheet
Executive SummaryFDA, CMS and other agencies within the Department of Health and Human Services will combine forces to improve and standardize analytical tools used in regulatory decision-making.
You may also be interested in...
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.